The present disclosure relates to crystalline solid forms of a stimulator of soluble guanylate cyclase (sGC), Compound I: ##STR00001##
Also provided herein are methods for the preparation of these solid forms. The invention also relates to pharmaceutical formulations and dosage forms comprising these solid forms and their uses thereof, alone or in combination with one or more additional agents, for treating and/or preventing various diseases or disorders; these diseases or disorders are ones that may benefit from sGC stimulation or from an increase in the concentration of nitric oxide (NO) and/or cyclic guanosine monophosphate (cGMP).

A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.

Described herein, inter alia, are certain substituted imidazo[1,5-a]pyrazines of formula (I) and methods of using the same for modulating the activity of Ire1. ##STR00001##

Provided herein are methods for the prevention and treatment of cardiovascular diseases and disorders in a subject diagnosed as having suffered a cerebrovascular injury by administering agents that contain or induce the expression of microRNA-126.

Provided herein are methods for the prevention and treatment of cardiovascular diseases and disorders in a subject diagnosed as having suffered a cerebrovascular injury by administering agents that contain or induce the expression of microRNA-126.

The presented invention relates to Omecamtiv mecarbil salts with methane sulfonic acid, benzene sulfonic acid and p-toluene sulfonic acid and to processes for preparation thereof.

The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease as a sole agent or in combination with other active ingredients.

Provided are compounds of Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2A, R.sup.2B, R.sup.3, R.sup.4, and R.sup.5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Provided are compounds of Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2A, R.sup.2B, R.sup.3, R.sup.4, and R.sup.5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Provided herein are tablet formulations comprising a core comprising omecamtiv mecarbil, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate of a pharmaceutically acceptable salt thereof; a filler; a binder; a glidant; and a lubricant; and a film coating on the core, the film coating comprising a modified-release polymer and a pore former. Also provided is a process for making a tablet formulation and a method of treating cardiovascular conditions, such as heart failure, using the tablet formulation.